The Role of Butirprost in Combination With Antibiotics in Chronic Bacterial Prostatitis (CBP) Treatment
Status:
COMPLETED
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Bacterial prostatitis (BP) is a common prostatic infection characterized by pain and urinary symptoms, often with negative bacterial cultures from prostatic secretions. It affects young and older men bimodally and significantly impacts quality of life (QoL). Treatment typically involves antibiotics, but a multimodal approach with additional nutraceuticals may enhance outcomes. This work aims to assess the efficacy of Butirprost in association with fluoroquinolones in patients with Chronic Bacterial Prostatitis (CBP).